New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hanwha Solarone Co Ltd (NASDAQ:HSOL), Neuralstem, Inc (NYSEMKT:CUR), Antares Pharma Inc (NASDAQ:ATRS), North American Palladium Ltd (USA) (NYSEMKT:PAL)
Hanwha Solarone Co Ltd (NASDAQ:HSOL) showed a volume of 1.88 million shares by the end of last trade whereas the average volume of the stock remained 2.28 million shares. The stock opened the session at $2.58 but then moved to $2.62. At that price, the stock showed a positive performance of 1.55%. Hanwha SolarOne Co., Ltd. (Hanwha SolarOne) is an integrated manufacturer of silicon ingots, silicon wafers, PV cells and PV modules in China. The Company manufactures a range of silicon ingots, silicon wafers, Photovoltaic (PV) cells and PV modules using advanced manufacturing process technologies that have helped the Company to increase its operational efficiency. The Company also provides PV module processing services.
Will HSOL Continue To Move Higher? Find Out Here
Neuralstem, Inc (NYSEMKT:CUR) opened the session at $3.05 and closed the session at $3.05. The stock showed a positive performance of 0.33% in previous trading session. Traded with volume of 1.88 million shares in the prior session and the average volume of the stock remained 1.07 million shares. Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.
For How Long CUR will fight for Profitability? Read This Trend Analysis report
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.58 and closed the session at $4.41. The stock showed a negative performance of -3.50% in previous trading session. Traded with volume of 1.86 million shares in the prior session and the average volume of the stock remained 1.59 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Why Should Investors Buy ATRS After the Recent Fall? Just Go Here and Find Out
North American Palladium Ltd (USA) (NYSEMKT:PAL) the stock advanced 2.73% and finished the session at $0.650. Traded with volume of 1.86 million shares in the prior session and the average volume of the stock remained 4.27 million shares. The beta of the stock remained 2.36. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals.
Will PAL Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)